Literature DB >> 12932390

Clinical xenotransplantion--how close are we?

David K C Cooper1.   

Abstract

CONTEXT: Xenotransplantation with pig organs offers a medium-term solution to the shortage of organs available for clinical transplantation. The immunological barriers to xenotransplantation have been, and remain, formidable. In the early 1990s, the identification of Galalpha1,3Gal (Gal) as the main target for human xenoreactive (anti-pig) antibodies and the development of pigs transgenic for a human complement regulatory protein, decay-accelerating factor (hDAF), were major advances. The presence of hDAF on the vascular endothelium of pig organs provided some protection against complement-mediated hyperacute rejection. This protection, however, was short-lived, and, until recently, the longest median time for organ survival that had been achieved (with combinations of biological and pharmacological immunosuppressants) in a series of pig-to-primate organ transplants was under a month. STARTING POINT: Christopher McGregor and colleagues recently reported to the International Society of Heart and Lung Transplantation (J Heart Lung Transplant 2003; 22: S89) that, by combining the use of organs which express hDAF with the administration of a soluble Gal glycoconjugate and other immunosuppressive agents, the survival of pig hearts in baboons can be extended to a median of 76 days. McGregor's work suggests that immunological barriers to xenotransplantation are not insurmountable. WHERE NEXT? The recent generation of pigs that do not express Gal epitopes (alpha1,3-galactosyltransferase gene-knockout pigs) might remove the need both for the expression of hDAF and the administration of a soluble Gal glycoconjugate. The absence of a natural antibody response will allow investigation of the cellular immune response and of any molecular incompatibilities between pig and primate that may be detrimental to graft survival. Furthermore, the absence of a humoral response may open the way for the induction of immunological tolerance (or unresponsiveness in the absence of exogenous immunosuppression) to a transplanted pig organ.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932390     DOI: 10.1016/S0140-6736(03)14118-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

1.  Histopathologic and immunohistochemical comparison of human, rabbit, and swine aneurysms embolized with platinum coils.

Authors:  Daying Dai; Yong Hong Ding; Mark A Danielson; Ramanathan Kadirvel; Debra A Lewis; Harry J Cloft; David F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2005 Nov-Dec       Impact factor: 3.825

2.  Education and research using experimental pigs in a medical school.

Authors:  Hozumi Tanaka; Eiji Kobayashi
Journal:  J Artif Organs       Date:  2006       Impact factor: 1.731

3.  Analysis of substrate specificity of pig CYP2B22 and CYP2C49 towards herbicides by transgenic rice plants.

Authors:  Hiroyuki Kawahigashi; Sakiko Hirose; Kenjirou Ozawa; Yoshiko Ido; Misaki Kojima; Hideo Ohkawa; Yasunobu Ohkawa
Journal:  Transgenic Res       Date:  2005-12       Impact factor: 2.788

4.  Scan of the endogenous retrovirus sequences across the swine genome and survey of their copy number variation and sequence diversity among various Chinese and Western pig breeds.

Authors:  Jia-Qi Chen; Ming-Peng Zhang; Xin-Kai Tong; Jing-Quan Li; Zhou Zhang; Fei Huang; Hui-Peng Du; Meng Zhou; Hua-Shui Ai; Lu-Sheng Huang
Journal:  Zool Res       Date:  2022-05-18

5.  Suppressive efficacy and proliferative capacity of human regulatory T cells in allogeneic and xenogeneic responses.

Authors:  Yih-Jyh Lin; Hidetaka Hara; Hao-Chih Tai; Cassandra Long; Daisuke Tokita; Peter Yeh; David Ayares; Adrian E Morelli; David K C Cooper
Journal:  Transplantation       Date:  2008-11-27       Impact factor: 4.939

6.  Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model.

Authors:  Gil Hecht; Smadar Eventov-Friedman; Chava Rosen; Elias Shezen; Dalit Tchorsh; Anna Aronovich; Enrique Freud; Hana Golan; Ronit El-Hasid; Helena Katchman; Bernhard J Hering; Amnon Zung; Zipi Kra-Oz; Pninit Shaked-Mishan; Alex Yusim; Alex Shtabsky; Pavel Idelevitch; Ana Tobar; Alon Harmelin; Esther Bachar-Lustig; Yair Reisner
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

7.  Rejection of cardiac xenografts transplanted from alpha1,3-galactosyltransferase gene-knockout (GalT-KO) pigs to baboons.

Authors:  Y Hisashi; K Yamada; K Kuwaki; Y-L Tseng; F J M F Dor; S L Houser; S C Robson; H-J Schuurman; D K C Cooper; D H Sachs; R B Colvin; A Shimizu
Journal:  Am J Transplant       Date:  2008-12       Impact factor: 8.086

8.  Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons.

Authors:  Akira Shimizu; Yosuke Hisashi; Kenji Kuwaki; Yau-Lin Tseng; Frank J M F Dor; Stuart L Houser; Simon C Robson; Henk-Jan Schuurman; David K C Cooper; David H Sachs; Kazuhiko Yamada; Robert B Colvin
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

Review 9.  Precision editing of large animal genomes.

Authors:  Wenfang Spring Tan; Daniel F Carlson; Mark W Walton; Scott C Fahrenkrug; Perry B Hackett
Journal:  Adv Genet       Date:  2012       Impact factor: 1.944

10.  In vitro culturing of porcine tracheal mucosa as an ideal model for investigating the influence of drugs on human respiratory mucosa.

Authors:  Eberhard Stennert; Oliver Siefer; Meihua Zheng; Martin Walger; Axel Mickenhagen
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-05-06       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.